Phaseline

Companies › OnCusp Therapeutics

OnCusp Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CUSP06
Antibody drug conjugate (ADC)
–Phase 1Ovarian CancerMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06234423CUSP06Phase 1Ovarian CancerOncologyMay 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.